Candin for the Treatment of Common Warts

Inclusion Criteria: At least 3, but not more than 20 common warts (Verruca vulgaris) Willing to agree to use adequate contraception methods during the study Exclusion Criteria: Systemic or localized diseases, conditions, or medications that could interfere with the assessment of safety or efficacy or that compromise immune function Candin delayed type hypersensitivity reaction test wheal sized < 5 mm or > 25 mm at the Baseline Visit History of keloid formation Prior treatment of common warts with liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, salicylic acid, etc., that, in the Investigator's opinion, does not exhibit complete healing from the treatment Treatment with immunotherapy (e.g., diphenylcyclopropenone [DPCP], dinitrochlorobenzene [DNCB], or other), imiquimod, 5-fluorouracil, bleomycin, or podophyllin within 12 weeks of the Baseline Visit or during the study Prior treatment with Candida albicans within 12 weeks of the Baseline Visit or during the study Systemic treatment with an immunosuppressive drug during the study or in the 6 months or 5 half lives prior to the Baseline Visit or during the study (e.g., azathioprine, 6 mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids [topical or inhaled steroids are acceptable]). Use of cantharidin or an investigational agent or device within the 30 days prior to the Baseline Visit or during the study